Top Story

Aspirin, NSAIDs reduced risk for aggressive prostate cancer

September 29, 2014

Men with elevated PSA and a negative prostate biopsy who used aspirin and/or other NSAIDs demonstrated a significantly reduced risk for aggressive prostate cancer compared with those who did not use either type of agent, according to study results presented at the American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research.

The study included 6,390 men who had been included in the REDUCE study, which evaluated whether dutasteride (Avodart, GlaxoSmithKline) reduced risk for incident prostate cancer compared with placebo.

figure Meeting News Coverage

Shorter ADT regimen improved quality of life among men with high-risk prostate cancer

September 16, 2014
Men with high-risk prostate cancer who underwent treatment with radiotherapy plus 18 months of androgen deprivation therapy demonstrated improved testosterone recovery…
figure

Report: Commitment to NIH, NCI funding only 'viable path' for continued success in cancer research

September 16, 2014
The scientific community’s continued quest to prevent and cure cancer has reached a crossroads, according to a report released today by the American Association…
In the Journals

AR-V7 linked to treatment resistance in castration-resistant prostate cancer

September 16, 2014
Detectable androgen receptor splice variant-7 messenger RNA in circulating tumor cells was associated with resistance to enzalutamide and abiraterone in men with…
CME
figure

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
Meeting News Coverage Video
figure

Docetaxel plus ADT improved OS in metastatic prostate cancer

June 24, 2014
CHICAGO — Donald L. Trump, MD, FACP, president and CEO at Roswell Park Cancer Institute and HemOnc Today
More »
CME
figure

Applying Imaging, Biomarkers, and Immunotherapy in the Management of NSCLC

This activity is supported by an educational grant from Genentech, Inc.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, but the numerous subtypes make this disease…
More »

Filter By:

Meeting News Coverage

Aspirin, NSAIDs reduced risk for aggressive prostate cancer

September 29, 2014
Men with elevated PSA and a negative prostate biopsy who used aspirin and/or other NSAIDs demonstrated a significantly reduced risk for aggressive…
figure Meeting News Coverage

Shorter ADT regimen improved quality of life among men with high-risk prostate cancer

September 16, 2014
Men with high-risk prostate cancer who underwent treatment with radiotherapy plus 18 months of androgen deprivation therapy demonstrated improved…
figure

Report: Commitment to NIH, NCI funding only 'viable path' for continued success in cancer research

September 16, 2014
The scientific community’s continued quest to prevent and cure cancer has reached a crossroads, according to a report released today by the…
In the Journals

AR-V7 linked to treatment resistance in castration-resistant prostate cancer

September 16, 2014
Detectable androgen receptor splice variant-7 messenger RNA in circulating tumor cells was associated with resistance to enzalutamide and abiraterone…
Meeting News Coverage

High-dose radiation plus long-term ADT extended survival in prostate cancer

September 15, 2014
Men with intermediate or high-risk prostate cancer who underwent high-dose radiation therapy followed by a longer duration of androgen deprivation…
figure Meeting News Coverage

Toxins at Ground Zero linked with cancer among thousands of first responders

September 11, 2014
The tragedy of Sept. 11, 2001 still haunts Americans in countless ways, with many survivors continuing to struggle with the enduring grief and trauma…
Industry News

Cometriq fails to meet primary endpoint in metastatic castration-resistant prostate cancer

September 8, 2014
Results from a phase 3 trial have found that cabozantinib did not meet its primary endpoint of OS compared with prednisone for the treatment of…
In the Journals

Genomic analysis identified favorable treatment option after prostate cancer surgery

September 8, 2014
A genomic classifier may be effective in predicting the risk of biochemical failure and distant metastasis in post-surgery radiation in patients with…
In the Journals

Prostate cancer prevention trial identified behaviors linked to biopsy adherence

September 5, 2014
Among participants in the Prostate Cancer Prevention Trial, those who complied with study requirements 1 year before the end of the study were more…
In the Journals

BRCA2 mutation associated with shorter survival in screen-detected prostate cancer

September 2, 2014
Men with screen-detected prostate cancer who harbor mutations in the BRCA2 gene demonstrated poorer-than-expected prognosis, according to study…
More Headlines »